These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 33895087)

  • 1. Artificial Intelligence-based Detection of FGFR3 Mutational Status Directly from Routine Histology in Bladder Cancer: A Possible Preselection for Molecular Testing?
    Loeffler CML; Ortiz Bruechle N; Jung M; Seillier L; Rose M; Laleh NG; Knuechel R; Brinker TJ; Trautwein C; Gaisa NT; Kather JN
    Eur Urol Focus; 2022 Mar; 8(2):472-479. PubMed ID: 33895087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using deep learning to identify bladder cancers with FGFR-activating mutations from histology images.
    Velmahos CS; Badgeley M; Lo YC
    Cancer Med; 2021 Jul; 10(14):4805-4813. PubMed ID: 34114376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The FGFR3 mutation is related to favorable pT1 bladder cancer.
    van Rhijn BW; van der Kwast TH; Liu L; Fleshner NE; Bostrom PJ; Vis AN; Alkhateeb SS; Bangma CH; Jewett MA; Zwarthoff EC; Zlotta AR; Bapat B
    J Urol; 2012 Jan; 187(1):310-4. PubMed ID: 22099989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma.
    Teo MY; Mota JM; Whiting KA; Li HA; Funt SA; Lee CH; Solit DB; Al-Ahmadie H; Milowsky MI; Balar AV; Pietzak E; Dalbagni G; Bochner BH; Ostrovnaya I; Bajorin DF; Rosenberg JE; Iyer G
    Eur Urol; 2020 Dec; 78(6):907-915. PubMed ID: 32753285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FGFR3 Mutational Activation Can Induce Luminal-like Papillary Bladder Tumor Formation and Favors a Male Sex Bias.
    Shi MJ; Fontugne J; Moreno-Vega A; Meng XY; Groeneveld C; Dufour F; Kamoun A; Viborg Lindskrog S; Cabel L; Krucker C; Rapinat A; Dunois-Larde C; Lepage ML; Chapeaublanc E; Levrel O; Dixon V; Lebret T; Almeida A; De Reynies A; Rochel N; Dyrskjøt L; Allory Y; Radvanyi F; Bernard-Pierrot I
    Eur Urol; 2023 Jan; 83(1):70-81. PubMed ID: 36273937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A deep-learning workflow to predict upper tract urothelial carcinoma protein-based subtypes from H&E slides supporting the prioritization of patients for molecular testing.
    Angeloni M; van Doeveren T; Lindner S; Volland P; Schmelmer J; Foersch S; Matek C; Stoehr R; Geppert CI; Heers H; Wach S; Taubert H; Sikic D; Wullich B; van Leenders GJ; Zaburdaev V; Eckstein M; Hartmann A; Boormans JL; Ferrazzi F; Bahlinger V
    J Pathol Clin Res; 2024 Mar; 10(2):e12369. PubMed ID: 38504364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibroblast growth factor receptor (FGFR) gene amplifications are rare events in bladder cancer.
    Fischbach A; Rogler A; Erber R; Stoehr R; Poulsom R; Heidenreich A; Schneevoigt BS; Hauke S; Hartmann A; Knuechel R; Veeck J; Gaisa NT
    Histopathology; 2015 Apr; 66(5):639-49. PubMed ID: 24898159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FGFR3 mutational status and protein expression in patients with bladder cancer in a Jordanian population.
    Bodoor K; Ghabkari A; Jaradat Z; Alkhateeb A; Jaradat S; Al-Ghazo MA; Matalka I; Musleh H; Haddad Y
    Cancer Epidemiol; 2010 Dec; 34(6):724-32. PubMed ID: 20542753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular investigation of FGFR3 gene mutation and its correlation with clinicopathological findings in Indian bladder cancer patients.
    Ahmad F; Mahal V; Verma G; Bhatia S; Das BR
    Cancer Rep (Hoboken); 2018 Oct; 1(3):e1130. PubMed ID: 32721083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations.
    Lamy A; Gobet F; Laurent M; Blanchard F; Varin C; Moulin C; Andreou A; Frebourg T; Pfister C
    J Urol; 2006 Dec; 176(6 Pt 1):2686-9. PubMed ID: 17085196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors.
    Billerey C; Chopin D; Aubriot-Lorton MH; Ricol D; Gil Diez de Medina S; Van Rhijn B; Bralet MP; Lefrere-Belda MA; Lahaye JB; Abbou CC; Bonaventure J; Zafrani ES; van der Kwast T; Thiery JP; Radvanyi F
    Am J Pathol; 2001 Jun; 158(6):1955-9. PubMed ID: 11395371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deep Learning Predicts Molecular Subtype of Muscle-invasive Bladder Cancer from Conventional Histopathological Slides.
    Woerl AC; Eckstein M; Geiger J; Wagner DC; Daher T; Stenzel P; Fernandez A; Hartmann A; Wand M; Roth W; Foersch S
    Eur Urol; 2020 Aug; 78(2):256-264. PubMed ID: 32354610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Correlation of FGFR3 mutations and chromosomal alterations in bladder cancer].
    Junker K; van Oers JM; Zwarthoff EC; Kania I; Schubert J; Hartmann A
    Verh Dtsch Ges Pathol; 2006; 90():151-8. PubMed ID: 17867592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Fully Automated Artificial Intelligence System to Assist Pathologists' Diagnosis to Predict Histologically High-grade Urothelial Carcinoma from Digitized Urine Cytology Slides Using Deep Learning.
    Tsuji K; Kaneko M; Harada Y; Fujihara A; Ueno K; Nakanishi M; Konishi E; Takamatsu T; Horiguchi G; Teramukai S; Ito-Ihara T; Ukimura O
    Eur Urol Oncol; 2024 Apr; 7(2):258-265. PubMed ID: 38065702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic and Prognostic Implications of FGFR3
    Geelvink M; Babmorad A; Maurer A; Stöhr R; Grimm T; Bach C; Knuechel R; Rose M; Gaisa NT
    Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30154342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibroblast growth factor receptor 3 mutation in voided urine is a useful diagnostic marker and significant indicator of tumor recurrence in non-muscle invasive bladder cancer.
    Miyake M; Sugano K; Sugino H; Imai K; Matsumoto E; Maeda K; Fukuzono S; Ichikawa H; Kawashima K; Hirabayashi K; Kodama T; Fujimoto H; Kakizoe T; Kanai Y; Fujimoto K; Hirao Y
    Cancer Sci; 2010 Jan; 101(1):250-8. PubMed ID: 19843069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors.
    Zieger K; Dyrskjøt L; Wiuf C; Jensen JL; Andersen CL; Jensen KM; Ørntoft TF
    Clin Cancer Res; 2005 Nov; 11(21):7709-19. PubMed ID: 16278391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive
    Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
    Front Immunol; 2022; 13():931906. PubMed ID: 35958598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment.
    Pouessel D; Neuzillet Y; Mertens LS; van der Heijden MS; de Jong J; Sanders J; Peters D; Leroy K; Manceau A; Maille P; Soyeux P; Moktefi A; Semprez F; Vordos D; de la Taille A; Hurst CD; Tomlinson DC; Harnden P; Bostrom PJ; Mirtti T; Horenblas S; Loriot Y; Houédé N; Chevreau C; Beuzeboc P; Shariat SF; Sagalowsky AI; Ashfaq R; Burger M; Jewett MA; Zlotta AR; Broeks A; Bapat B; Knowles MA; Lotan Y; van der Kwast TH; Culine S; Allory Y; van Rhijn BW
    Ann Oncol; 2016 Jul; 27(7):1311-6. PubMed ID: 27091807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibroblast growth factor receptor (FGFR) alterations in squamous differentiated bladder cancer: a putative therapeutic target for a small subgroup.
    Baldia PH; Maurer A; Heide T; Rose M; Stoehr R; Hartmann A; Williams SV; Knowles MA; Knuechel R; Gaisa NT
    Oncotarget; 2016 Nov; 7(44):71429-71439. PubMed ID: 27669755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.